»Call Us 336-396-3916

» Animal Health News & Notes for September 13, 2019

September 13, 2019
Print page

Brakke Consulting’s
Animal Health News & Notes for September 13, 2019
Copyright © Brakke Consulting

Editor: Lynn Fondon DVM MBA
************************************

IN THE NEWS:

Brakke Consulting News
Regulatory assistance

Earnings News
Avivagen

Other News

ACE Laboratory Services
Aga Nanotech
Alltech
Apiam Animal Health
Archbold Biological Station
ASPCA Pet Health Insurance
Biotecon Diagnostics
Branford Castle Partners
Candioli Pharma
Centro Sperimentale del Latte
Ceva
CombiGene
Crum & Forster Pet Insurance Group
ECO Animal Health
GAMA Healthcare
Heska
IDEXX
ImmuCell
Intervacc
Kindred Biosciences
Norbrook
Panion Animal Health
Phoenix Central Laboratory
Pulse Veterinary Technologies
Virbac

***********************************
BRAKKE CONSULTING
Product Development and Regulatory Affairs Assistance

Did you know that Brakke Consulting can provide your company with product development and regulatory affairs assistance in the animal health vaccine, diagnostics, and drug segments for both food and companion animals?

Brakke Consulting has the experience, insight, ability and contacts to provide clients with high quality, product-specific consulting services in the areas of technology assessment, product development, manufacturing, and regulatory affairs. Let Brakke Consulting assist you in moving your project from proof-of-concept right on through to commercialization.

To learn more about how we can help, please contact info@brakkeconsulting.com or Mike McGinley directly at mjmcginley813@gmail.com for a confidential consultation.

www.BrakkeConsulting.com

***********************************

 


COMPANY EARNINGS RELEASES

  • Avivagen announced its unaudited financial results for the third quarter of 2019. Revenues were C$12,484 (US$9,480), a decrease of C$351,729 over the three-month period ended July 31, 2018. The difference was due to timing of sales, as sales that had been expected for this quarter were realized in August. The comprehensive loss from continuing operations for the three-month period ended July 31, 2019 was C$(1.3) million (US$0.99 million). (company press release)

**********************************
REGULATORY SEMINAR
Animal Pharmaceuticals Supply Chain Interruptions: An Interactive Seminar on why Interruptions Occur and Best Practices for Mitigation
PRESENTED BY KANSAS STATE UNIVERSITY OLATHE
SEPTEMBER 26, 2019

Supply chain interruptions can cause significant impact for the health and well-being of animals. This hands-on workshop will utilize current industry case studies to engage participants in analyzing supply chain interruptions to understand why they occur; what can be done to prevent them; and ways to enhance communication in the process. Attendees will also hear from experts on the topic from Industry, K-State and FDA CVM to share animal health supply chain best practices, as well as discuss risk management tools.

Early registration (by Sept. 6) for the day-long seminar is $200 which includes lunch; registration after this date is $250.

For more information or to register, go to https://olathe.k-state.edu/professional-dev/workshops/regulatory-affairs/.

**********************************
COMPANY NEWS RELEASES

  • Biotecon Diagnostics, in co-operation with Ceva, announced the launch of the vetproof STM Vaccine Detection Kit, a new DNA-based test that detects and differentiates accurately between the vaccine strains and field strains of Salmonella Typhimurium (STM) on swine farms. If salmonella is found on a farm by established methods, differentiation can be carried out on any substrate, with results achieved overnight or within 24 hours compared with five days for existing tests. (company press release)

  • Cascadia Capital LLC, an investment banking firm, announced it is soliciting buyers on behalf of Phoenix Central Laboratory, a regional reference laboratory. Phoenix derives its clientele mainly from Oregon, Northern California, Washington and Alaska. The sale follows an unsuccessful takeover bid by IDEXX that was encouraged by a shareholder and former board member. (VIN News)

  • ImmuCell announced that it has entered into a new agreement with Norbrook Laboratories, Limited covering the formulation and aseptic filling of its Nisin Drug Substance into syringes for Re-Tain, the Company’s novel treatment in development for subclinical mastitis in dairy cows. The new agreement (which replaces an expiring agreement) covers the final development work required to achieve FDA approval and also provides product for market launch. (company press release)

  • Heska announced it is proposing a private offering of convertible senior notes, due 2026, valued at an aggregate principal amount of $75 million. The firm also expects to grant initial purchasers a 13-day option to purchase up to an additional $11.25 million aggregate principal amount of notes. (Animal Pharm)

  • Kindred Biosciences, Inc. announced that it has been selected by the National Cancer Institute (NCI) as one of three contractors in response to the solicitation for the PREVENT Cancer Preclinical Drug Development Program (PREVENT). As a cGMP pool contractor, KindredBio is eligible to provide manufacturing, formulation and analytical services to meet the needs of the PREVENT pipeline. A maximum amount of $49.95 million will be shared across three contract pools, one of which is the cGMP manufacturing pool. The contract term is four years, with specific amounts based on individual task order awards yet to be determined. (PRNewswire)

  • ASPCA Pet Health Insurance, a brand of Crum & Forster Pet Insurance Group, announced that health insurance for companion horses is now available in 12 states. California, Colorado, Connecticut, Kentucky, Oklahoma and Texas are the newest insurance territories, joining New York, New Jersey, Ohio, Pennsylvania, Virginia and Wisconsin. (Todays Veterinary Business)

  • Panion Animal Health announced it has withdrawn the investigational new animal drug (INAD) application for its epilepsy gene therapy for dogs to avoid any fees for the 2020 fiscal year. The company recently reshuffled its organizational structure after CombiGene became a major shareholder in the firm, and the clinical study of its gene therapy is on hold until the decisions of an extraordinary general assembly called by CombiGene have been finalized. (Animal Pharm)

  • Branford Castle Partners announced it has acquired Pulse Veterinary Technologies LLC (PulseVet), a provider of shock wave therapy devices for the veterinary industry. Financial terms were not disclosed. (PEHub.com)

  • Alltech announced a collaboration with Archbold Biological Station to better understand cattle production approaches. The goals of the project are to: increase the quality and quantity of beef produced in subtropical regions; understand cattle production’s impact on the environment; and develop supplementation strategies that can reduce cattle methane emissions and enhance sustainability. (Animal Pharm)

  • UK Virbac announced the UK launch of Multimin, a prescription-only, four-in-one trace mineral injection for oxidative stress and its effects in cattle. The product contains copper, manganese, selenium and zinc, and is designed to be administered before or during periods of high demand in dairy and beef cattle, like breeding, calving, weaning and vaccination, and is not subject to interactions and absorption effects in the rumen. (Zenopa)

  • UK ECO Animal Health Ltd announced that it has entered into a second worldwide exclusive research partnership with The Pirbright Institute to develop another novel vaccine for use in chickens. Innovative technologies developed at Pirbright will use a Marek’s disease virus vector to express multiple protective components against the economically important poultry viral diseases of infectious bursal disease virus (IBDV), Newcastle disease virus (NDV) and infectious laryngotracheitis virus (ILTV). (company press release)

  • SWEDEN Intervacc announced it has raised SEK62 million ($6.3 million) following the sale of shares to three investors. The share issue will finance continued commercialization efforts for Strangvac and development of the firm’s other vaccines. (Animal Pharm)

  • AUSTRALIA Apiam Animal Health announced it has agreed to buy ACE Laboratory Services, Australia’s biggest custom vaccine and diagnostic laboratory, for A$16 million. (afr.com)

  • EU Italian firms Candioli Pharma and Centro Sperimentale del Latte announced a partnership to develop a probiotic for companion animals using a strain of Lactobacillus acidophilus Candioli has gained registration with the European Food Safety Authority for the product, and is building a network of partners that will use the strain in nutritional supplements and pet food. (Animal Pharm)

  • UK GAMA Healthcare announced a partnership with Scotland’s Rural College (SRUC), the Centre for Innovation Excellence in Livestock (CIEL) and the Shanghai Veterinary Research Institute in China to customize and trial an innovative, patented technology for use in poultry that targets antimicrobial resistance in poultry. The technology, held by Aga Nanotech — a sister company to GAMA Healthcare — couples a cancer medicine delivery system with reactive, short-lived antiseptic compounds. The loaded nanoparticles have been shown in the laboratory to be effective in treating antibiotic-resistant bacteria. (Feedstuffs)

***********************************

ANIMAL HEALTH STOCK PRICE TRACKER

*Thursday market closing prices

***********************************
ANIMAL HEALTH NEWS

  • US – GENE EDITING FDA scientists have found that a bull treated with a new gene-editing technology to keep it from growing horns also developed antibiotic resistance. According to the FDA, an “unintended” addition of DNA from a different species occurred during the gene-editing process. It went undetected by Recombinetics, the company that developed the technology. (Vet Advantage – MIT Technology Review)

  • US – VETERINARY EDUCATION Texas A&M and West Texas A&M University (WT) announced a new  partnership that will allow veterinary students to take their first and second-year classes through the Veterinary, Education, Research, and Outreach (VERO) Center on WT’s campus in Canyon, TX. Students will travel to Texas A&M’s main campus in College Station, TX for their final two years of classes. The 2+2 program also gives veterinary students wanting to work in food animal or mixed animal medicine the opportunity to return to the VERO for part of their final year of clinical rotations. 20 first and second-year DVM students will be accepted into the program, and fourth-year veterinary students will begin clinical rotations here in the panhandle next year. (myhighplains.com, abc7amarillo.com)

************************************
BRAKKE CONSULTING VIEWPOINT

Yesterday, John Volk and I attended Banfield Pet Hospital’s 18th Annual Pet Healthcare Industry Summit in Portland, Oregon.  This year’s event focused on the availability of veterinarians to meet the increasing demand for veterinary services, the quality of the talent in the applicant pool and veterinary hospital ownership trends.  Other topics covered at the meeting included the level of diversity in the veterinary profession and how the industry can change it, as well as how the veterinary schools are training Generation Z, which were born from 1996 to 2015, are the students entering veterinary school now.

The generational changes ahead of us from Gen Z was presented by Cam Marston.  From what he presented and what we know, the Gen Z population value more from a job than just the salary, and compared to Millennials, born between 1980 and 1985, they are more skeptical and trust their employers less.  Gen Z’ers are also less willing than Millennials to pay extra for customer experience and are more focused on saving money rather than the experience.  Perhaps Gen Zers will be less likely to attend veterinary schools that require life-changing levels of debt and maybe they will find substitutes for expensive veterinary care.

The industry, or rather, the market, will figure out how Gen Z pet owners will receive and how Gen Z veterinarians will provide veterinary medical services in the future.  Thanks to Banfield from both John and I for facilitating a complicated and important discussion.

Bob Jones

**********************************

Trouble viewing this newsletter?  You can view it online at www.BrakkeConsulting.com

This electronic newsletter is the sole property of Brakke Consulting.
Any use of the contents herein should be approved by and appropriately attributed to Brakke Consulting.

For more information about Brakke Consulting’s services and syndicated studies, visit our website at www.brakkeconsulting.com.
Brakke Consulting

806 Green Valley Rd
Suite 200
Greensboro, NC  27408